Palir Neža, Ruiter Jos P N, Wanders Ronald J A, Houtkooper Riekelt H
Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
J Lipid Res. 2017 May;58(5):955-961. doi: 10.1194/jlr.M075317. Epub 2017 Mar 9.
In recent years the short-chain fatty acid, 4-phenylbutyrate (PB), has emerged as a promising drug for various clinical conditions. In fact, PB has been Food and Drug Administration-approved for urea cycle disorders since 1996. PB is more potent and less toxic than its metabolite, phenylacetate (PA), and is not just a pro-drug for PA, as was initially assumed. The metabolic pathway of PB, however, has remained unclear. Therefore, we set out to identify the enzymes involved in the β-oxidation of PB. We used cells deficient in specific steps of fatty acid β-oxidation and ultra-HPLC to measure which enzymes were able to convert PB or its downstream products. We show that the first step in PB oxidation is catalyzed solely by the enzyme, medium-chain acyl-CoA dehydrogenase. The second (hydration) step can be catalyzed by all three mitochondrial enoyl-CoA hydratase enzymes, i.e., short-chain enoyl-CoA hydratase, long-chain enoyl-CoA hydratase, and 3-methylglutaconyl-CoA hydratase. Enzymes involved in the third step include both short- and long-chain 3-hydroxyacyl-CoA dehydrogenase. The oxidation of PB is completed by only one enzyme, i.e., long-chain 3-ketoacyl-CoA thiolase. Taken together, the enzymatic characteristics of the PB degradative pathway may lead to better dose finding and limiting the toxicity of this drug.
近年来,短链脂肪酸4-苯丁酸(PB)已成为一种有望用于多种临床病症的药物。事实上,自1996年以来,PB已获美国食品药品监督管理局批准用于尿素循环障碍。PB比其代谢产物苯乙酸(PA)更有效且毒性更低,并且并不像最初所认为的那样仅仅是PA的前体药物。然而,PB的代谢途径仍不清楚。因此,我们着手确定参与PBβ-氧化的酶。我们使用脂肪酸β-氧化特定步骤缺陷的细胞和超高效液相色谱法来测定哪些酶能够转化PB或其下游产物。我们发现,PB氧化的第一步仅由中链酰基辅酶A脱氢酶催化。第二步(水合作用)可由所有三种线粒体烯酰辅酶A水合酶催化,即短链烯酰辅酶A水合酶、长链烯酰辅酶A水合酶和3-甲基戊二酰辅酶A水合酶。参与第三步的酶包括短链和长链3-羟基酰基辅酶A脱氢酶。PB的氧化仅由一种酶即长链3-酮酰基辅酶A硫解酶完成。综上所述,PB降解途径的酶学特性可能有助于更好地确定剂量并限制该药物的毒性。